دورية
PP.35.03
| العنوان: | PP.35.03 |
|---|---|
| المؤلفون: | Zannad>, F.>, Rasmussen, H.S., Lavin, P.T., Singh, B., Yang, A., Anker, S.D. |
| المصدر: | Journal of Hypertension; June 2015, Vol. 33 Issue: Supplement 1 pe450-e451, 2p |
| مستخلص: | Inhibitors of the renin-angiotensin-aldosterone system (RAAS) increase the risk of hyperkalaemia (serum K >5.0mmolL). This often leads to suboptimal dosing or RAASi treatment discontinuation, despite proven benefit in hypertensive and chronic kidney disease (CKD) patients. Sodium zirconium cyclosilicate (ZS-9) is a non-absorbed cation exchanger specifically designed to trap excess K in the gastrointestinal (GI) tract. ZS-9 rapidly controlled normal serum K in 2 Phase 3 trials (Packham, NEJM 2014; Kosiborod, JAMA 2014). Here we present results from a pre-specified analysis of patients from the Phase 3 HARMONIZE study who were receiving RAASi. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 02636352 14735598 |
|---|---|
| DOI: | 10.1097/01.hjh.0000468799.18826.ad |